Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.40 |
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.36 |
| ▸ | CDK9 | P50750 | 5/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19102376 | 0.80 | FLT3 (0.39) | FLT3SMPD3PIK3CACCNT1CDK9 | |
| SCHEMBL3037759 | 0.80 | FLT3 (0.39) | FLT3SMPD3PIK3CACCNT1CDK9 | |
| SCHEMBL25157822 | 0.80 | PIK3CA (0.43) | FLT3SMPD3PIK3CACCNT1CDK9 | |
| SCHEMBL31441660 | 0.80 | CHRNA7 (0.35) | SMPD3CHRNA7HTR3A | |
| SCHEMBL22089810 | 0.80 | SMPD3 (0.57) | FLT3SMPD3PIK3CA | |
| SCHEMBL17759350 | 0.76 | FLT3 (0.44) | FLT3PIK3CACCNT1CDK9CDK7 | |
| SCHEMBL22330378 | 0.76 | FLT3 (0.39) | FLT3SMPD3PIK3CACCNT1CDK9 | |
| SCHEMBL22097433 | 0.76 | FLT3 (0.39) | FLT3SMPD3PIK3CACCNT1CDK9 | |
| SCHEMBL25158727 | 0.76 | FLT3 (0.36) | FLT3SMPD3PIK3CA | |
| SCHEMBL16553434 | 0.76 | FLT3 (0.40) | FLT3SMPD3PIK3CACCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119462666-A | Heterocyclic compound and application thereof | 谱度众合(武汉)生命科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3812387-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3409278-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200102313-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-3409278-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Tolero Pharmaceuticals, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-2734205-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9416132-B2 | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2734205-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Tolero Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013013188-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM2, PIM1, PIM3 | FLT3 364/4885SMPD3 4303/4885PIK3CA 136/4885 |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | FLT3 66/4885SMPD3 4253/4885PIK3CA 68/4885 |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | FLT3 120/4885SMPD3 4180/4885PIK3CA 341/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | FLT3 120/4885SMPD3 4180/4885PIK3CA 341/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | FLT3 120/4885SMPD3 4180/4885PIK3CA 341/4885 |
| US-20200102313-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | FLT3 120/4885SMPD3 4180/4885PIK3CA 341/4885 |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | FLT3 126/4885SMPD3 3898/4885PIK3CA 389/4885 |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM1, PIM2, PIM3 | FLT3 100/4885SMPD3 4280/4885PIK3CA 313/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | FLT3 120/4885SMPD3 4180/4885PIK3CA 341/4885 |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | FLT3 120/4885SMPD3 4180/4885PIK3CA 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.